X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (348) 348
humans (333) 333
simeprevir (290) 290
hepatitis c (257) 257
ribavirin (231) 231
hepatitis c, chronic - drug therapy (226) 226
sofosbuvir (220) 220
antiviral agents - therapeutic use (218) 218
hepatitis c virus (217) 217
gastroenterology & hepatology (191) 191
male (191) 191
drug therapy, combination (187) 187
female (187) 187
middle aged (185) 185
hepacivirus - genetics (167) 167
genotype (157) 157
interferon (145) 145
treatment-naive patients (144) 144
treatment outcome (136) 136
hepatitis (126) 126
aged (124) 124
adult (108) 108
pegylated interferon (108) 108
ribavirin - therapeutic use (106) 106
antiviral agents (103) 103
antiviral agents - administration & dosage (99) 99
cirrhosis (97) 97
simeprevir - therapeutic use (96) 96
hepacivirus - drug effects (95) 95
antiviral agents - adverse effects (92) 92
sustained virological response (92) 92
daclatasvir (90) 90
hepatitis c - drug therapy (90) 90
health aspects (88) 88
liver (86) 86
pharmacology & pharmacy (84) 84
infection (83) 83
sofosbuvir - therapeutic use (82) 82
therapy (82) 82
virus-infection (82) 82
genotype 1 infection (81) 81
ledipasvir (81) 81
liver cirrhosis (81) 81
hepatitis c, chronic - virology (79) 79
care and treatment (76) 76
infectious diseases (76) 76
double-blind (75) 75
hcv (75) 75
plus ribavirin (75) 75
biological response modifiers (74) 74
genotype 1 (74) 74
liver transplantation (73) 73
telaprevir (69) 69
transplantation (68) 68
analysis (66) 66
drug therapy (64) 64
genetic aspects (62) 62
patients (59) 59
simeprevir - administration & dosage (59) 59
genotype & phenotype (58) 58
infections (58) 58
ribavirin - administration & dosage (58) 58
direct-acting antivirals (57) 57
simeprevir plus sofosbuvir (57) 57
protease inhibitors (56) 56
sustained virologic response (56) 56
hepatitis c, chronic - complications (55) 55
retrospective studies (54) 54
interferon-alpha 2a (50) 50
sofosbuvir - administration & dosage (49) 49
uridine monophosphate - analogs & derivatives (49) 49
interferon-alpha - therapeutic use (48) 48
boceprevir (47) 47
treatment-naive (47) 47
safety (45) 45
simeprevir - adverse effects (44) 44
viruses (44) 44
imidazoles - therapeutic use (43) 43
sulfonamides - therapeutic use (43) 43
hepatology (42) 42
phase-3 (42) 42
gastroenterology and hepatology (41) 41
plus sofosbuvir (40) 40
recurrence (40) 40
chronic hcv (38) 38
polyethylene glycols - therapeutic use (38) 38
virology (38) 38
virus diseases (38) 38
young adult (38) 38
proteases (37) 37
sofosbuvir - adverse effects (37) 37
antiviral therapy (36) 36
efficacy (36) 36
hepatitis c - virology (36) 36
hepatitis-c virus (36) 36
surgery (36) 36
ribavirin - adverse effects (35) 35
virus (35) 35
abridged index medicus (34) 34
fibrosis (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2015, Volume 148, Issue 4, pp. 762 - 770.e2
Journal Article
Journal Article
Journal Article
International Journal of Antimicrobial Agents, ISSN 0924-8579, 2017, Volume 49, Issue 3, pp. 296 - 301
Journal Article
Hepatology, ISSN 0270-9139, 09/2015, Volume 62, Issue 3, pp. 715 - 725
Journal Article
Journal Article
Annals of Hepatology, ISSN 1665-2681, 09/2018, Volume 17, Issue 5, pp. 815 - 821
Introduction and aim. Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen... 
Simeprevir | Direct acting antiviral agents (DAA) | Relapser | Hepatitis C | Sofosbuvir | Ledipasvir | TREATMENT-NAIVE | PLUS SOFOSBUVIR | C GENOTYPE 1 | INFECTION | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 2, pp. 419 - 429
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 09/2014, Volume 40, Issue 6, pp. 657 - 675
Summary Background Sofosbuvir, an oral NS5B nucleotide polymerase inhibitor, is indicated for the treatment of patients infected with hepatitis C virus (HCV).... 
UNITED-STATES | CARE COSTS | TELAPREVIR | POLYMERASE INHIBITOR | PEGYLATED INTERFERON | TRIPLE THERAPY | PHARMACOLOGY & PHARMACY | HCV | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | PROTEASE INHIBITORS | HEALTH-STATE UTILITIES | Simeprevir | HIV Infections - economics | Ribavirin - economics | Humans | Middle Aged | Hepacivirus - genetics | Uridine Monophosphate - economics | Liver Cirrhosis - economics | Polyethylene Glycols - economics | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Liver Cirrhosis - drug therapy | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Decision Support Techniques | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - economics | Proline - therapeutic use | Health Care Costs | Sulfonamides - therapeutic use | Cost-Benefit Analysis | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | HIV Infections - drug therapy | Antiviral Agents - economics | Hepatitis C, Chronic - genetics | Sofosbuvir | Analysis | Markov processes | Genetic aspects | Biological response modifiers | Cost benefit analysis | Hepatitis C virus | Health aspects | Liver cirrhosis
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article